Research Paper Volume 8, Issue 2 pp 345—365

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function


Figure 1. p63 expression in diffuse large B-cell lymphoma (DLBCL) in comparison with p53 expression. (A-B) Representative immunohistochemistry staining for p63 (10% and 95%) in DLBCL. (C-D) Histograms of p63 expression in the training and validation sets. (E) Comparisons between p63 and p53 expression levels in DLBCL. (F) Comparisons between TP63 and TP53 mRNA levels in DLBCL. (G) p63+ DLBCL had significantly higher levels of TP63 mRNA compared with p63 DLBCL. (H) p63+ DLBCL had significantly higher TP53 mRNA levels compared with p63 DLBCL. (I) Expression of p63 protein correlated with TP63 mRNA levels. The TP63 mRNA expression levels (Log2 values) were retrieved from the gene expression profiling data. The mean values of 3 probe-sets (1555581_a_at, 207382_at, 209863_s_at) for each patient were used. The relative mRNA level refers to the difference between the TP63 mRNA level for each patient and the mean TP63 mRNA level for the entire cohort. (J-K) Comparisons of p63 protein and TP63 mRNA expression levels between germinal center B-cell–like (GCB) and activated B-cell–like (ABC) subtypes of DLBCL patients.